Literature DB >> 19819453

Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome.

Nevio Taglieri1, Daniel J Fernandez-Berges, Wolfgang Koenig, Luciano Consuegra-Sanchez, José Maria Cruz Fernandez, Nicolas Roberto Robles, Pedro Luis Sánchez, Alfonso Castro Beiras, Pedro Maria Montes Orbe, Juan Carlos Kaski.   

Abstract

OBJECTIVE: Evaluation of renal function (RF) is important for management of patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Cystatin C, a sensitive marker of RF, appears to be also a marker of cardiovascular risk. Little is known regarding its predictive role in NSTE-ACS patients.
METHODS: We assessed 525 patients taking part in the "Systemic Inflammation Evaluation in patients with NSTE-ACS" (SIESTA) study. Patients were subdivided in quartiles according to cystatin C plasma concentrations (mg/L), i.e., Q1<0.81; Q2=0.81-0.92; Q3=0.93-1.10; Q4>or=1.11. Glomerular filtration rate (eGFR) was estimated using the modification of diet in renal disease (MDRD) equation. The study end-point was the composite of cardiac death, non-fatal myocardial infarction and unstable angina at 1-year follow up.
RESULTS: Few patients (0.8%) had severely impaired RF (MDRD<30ml/min/1.73m(2)). 157 patients reached (30%) the study end-point. Patients in Q3 and Q4 showed a higher cumulative probability of cardiac events compared to patients in the lowest quartile. On multivariable analysis, patients in Q3 and Q4 had an increased incidence of cardiac events (adjusted HR=1.57 95%CI 1.04-2.49; p=0.036). Patients with TIMI risk score >or=3 or in-hospital heart failure were also at higher risk for acute cardiac events. Conventional markers of RF, i.e., serum creatinine and eGRF, were not predictors for the study end-point.
CONCLUSIONS: Increased levels of cystatin C were an independent predictor of cardiac events at 1-year follow up in this contemporary series of Mediterranean patients with NSTE-ACS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19819453     DOI: 10.1016/j.atherosclerosis.2009.09.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  17 in total

1.  The potential of Cystatin C and small dense LDL as biomarkers of coronary artery disease risk in a young Indian population.

Authors:  Anjali Manocha; Flora Gupta; Rajneesh Jain; Seema Bhargava; Mamta Kankra; Sabari Das; L M Srivastava
Journal:  Mol Cell Biochem       Date:  2013-12-20       Impact factor: 3.396

Review 2.  Laboratory parameters of cardiac and kidney dysfunction in cardio-renal syndromes.

Authors:  Dinna N Cruz; Ching Yan Goh; Alberto Palazzuoli; Leo Slavin; Anna Calabrò; Claudio Ronco; Alan Maisel
Journal:  Heart Fail Rev       Date:  2011-11       Impact factor: 4.214

3.  Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease.

Authors:  Grazina Urbonaviciene; Guo Ping Shi; Sigitas Urbonavicius; Eskild W Henneberg; Jes S Lindholt
Journal:  Atherosclerosis       Date:  2011-02-18       Impact factor: 5.162

4.  Inflammatory Cytokines as Risk Factors for Mortality After Acute Cardiac Events.

Authors:  Aida Hamzic-Mehmedbasic
Journal:  Med Arch       Date:  2016-07-27

5.  Association of serum cystatin C levels with mortality in patients with acute type A aortic dissection.

Authors:  Wei-Zhong Feng; Jun-Qing Zhou; Guang-Mao Yu; Yong Zeng; Peng Xu
Journal:  Oncotarget       Date:  2017-08-30

6.  Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study).

Authors:  Razieh Hassannejad; Hamsa Sharrouf; Fahimeh Haghighatdoost; Ben Kirk; Farzad Amirabdollahian
Journal:  Nutrients       Date:  2021-06-30       Impact factor: 5.717

7.  Cystatin C Is Not Causally Related to Coronary Artery Disease.

Authors:  Patrik Svensson-Färbom; Peter Almgren; Bo Hedblad; Gunnar Engström; Margaretha Persson; Anders Christensson; Olle Melander
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

8.  Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses.

Authors:  Martin Magnusson; John Molvin; Gunnar Engström; Patrik Svensson-Färbom; Margaretha Persson; Anders Christensson; Peter Nilsson; Olle Melander
Journal:  PLoS One       Date:  2016-05-24       Impact factor: 3.240

9.  Cystatin C as a predictive marker of renal dysfunction and mid-term outcomes following off-pump coronary artery bypass grafting.

Authors:  Seung Hyun Lee; Young-Nam Youn; Hyun Chel Choo; Sak Lee; Kyung-Jong Yoo
Journal:  Heart       Date:  2015-07-27       Impact factor: 5.994

10.  Cystatin C in Acute Coronary Syndrome.

Authors:  Moushumi Lodh; Ashok Parida; Joy Sanyal; Arunangshu Ganguly
Journal:  EJIFCC       Date:  2013-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.